Rethink + Restore
We are developing first-in-class small molecules against a novel target to improve mitochondrial function and reduce chronic inflammation to treat age-related diseases.
Science
Vandria has identified a novel metabolic target with a unique mode of action across multiple age-related disease indications.
Pipeline
We have generated a novel pipeline of NCEs for patient impact across a broad range of age-related and chronic diseases of the CNS, muscle, lung and liver.
Our lead clinical CNS asset, VNA-318, is an orally available, first-in-class small molecule which has completed Phase I clinical studies.
Latest News
- Vandria announces first subjects dosed in its first-in-human Phase 1 clinical trial of VNA-318 brain-penetrant mitophagy inducer 18 December 2024
- Hevolution Foundation and Dolby Family Ventures join Vandria’s 2nd Series A closing, bringing the total round to $30.7M (CHF 28.3M) to Progress the Mitophagy Inducer VNA-318 into CNS Clinical Development 21 August 2024
